These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 19757200)

  • 21. [Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline].
    Hunyady B; Gervain J; Horváth G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I
    Orv Hetil; 2014 Mar; 155 Suppl():3-24. PubMed ID: 24631886
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of body mass index, cholesterol, triglycerides and steatosis on pegylated interferon alfa-2a and ribavirin treatment for recurrent hepatitis C in patients transplanted for HCV and alcoholic cirrhosis.
    Testino G; Sumberaz A; Ancarani AO; Borro P; Ravetti G; Ansaldi F; Andorno E; Gentile R; Icardi G
    Hepatogastroenterology; 2009; 56(90):501-3. PubMed ID: 19579629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans.
    Hu KQ; Currie SL; Shen H; Cheung RC; Ho SB; Bini EJ; McCracken JD; Morgan T; Bräu N; Schmidt WN; Jeffers L; Wright TL;
    Dig Dis Sci; 2007 Feb; 52(2):570-8. PubMed ID: 17226072
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis.
    Castéra L; Hézode C; Roudot-Thoraval F; Lonjon I; Zafrani ES; Pawlotsky JM; Dhumeaux D
    Gut; 2004 Mar; 53(3):420-4. PubMed ID: 14960527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Metabolic syndrome in patients with chronic hepatitis C genotype 1].
    Baĭzhanova ZhZh; Ignatova TM; Nekrasova TP; Abdurakhmanov DT
    Vestn Ross Akad Med Nauk; 2011; (1):3-7. PubMed ID: 21400720
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
    Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
    Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C virus genotype 4 infection in patients with normal serum ALT.
    Al-Ali J; Siddique I; Varghese R; Hasan F
    Ann Hepatol; 2012; 11(2):186-93. PubMed ID: 22345335
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation between insulin resistance and outcome of pegylated interferon and ribavirin therapy, hepatic steatosis, hepatic fibrosis in chronic hepatitis C-1b and high viral load.
    Kim SR; Saito J; Imoto S; Komaki T; Nagata Y; Nakajima T; Ando K; Fukuda K; Otono Y; Kim KI; Ohtani A; Sugimoto K; Hasegawa Y; Fujinami A; Ohta M; Hotta H; Maekawa Y; Hayashi Y; Kudo M
    Digestion; 2011; 84 Suppl 1():5-9. PubMed ID: 22156479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin.
    Guedj H; Guedj J; Negro F; Lagging M; Westin J; Bochud PY; Bibert S; Neumann AU;
    J Viral Hepat; 2012 Jul; 19(7):488-96. PubMed ID: 22676361
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
    Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
    J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improvement of steatosis after interferon therapy in HCV genotype 4 is related to weight loss.
    Esmat G; El Akel W; Metwally M; Soliman A; Doss W; Hamid MA; Kamal M; Zalata K; Khattab H; El-Kassas M; Esmat M; Hasan A; El-Raziky M
    Indian J Gastroenterol; 2009; 28(2):45-8. PubMed ID: 19696987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between PNPLA3[G]/I148M variant, steatosis and fibrosis stage in hepatitis C virus - genetic matters.
    Crisan D; Grigorescu M; Crisan N; Craciun R; Lupsor M; Radu C; Grigorescu MD; Suciu A; Epure F; Avram L; Leach N
    J Physiol Pharmacol; 2019 Aug; 70(4):. PubMed ID: 31642820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patients achieving clearance of HCV with interferon therapy recover from decreased retinol-binding protein 4 levels.
    Iwasa M; Hara N; Miyachi H; Tanaka H; Takeo M; Fujita N; Kobayashi Y; Kojima Y; Kaito M; Takei Y
    J Viral Hepat; 2009 Oct; 16(10):716-23. PubMed ID: 19302338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The role and possibilities of natural interferon treatment in chronic hepatitis C: experience with natural interferon treatment for patients barred from combined antiviral therapy because of the STOP rule].
    Horváth G; Tolvaj G; Halász T; Stotz G
    Orv Hetil; 2007 Aug; 148(33):1545-50. PubMed ID: 17686672
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Race, insulin resistance and hepatic steatosis in chronic hepatitis C.
    Conjeevaram HS; Kleiner DE; Everhart JE; Hoofnagle JH; Zacks S; Afdhal NH; Wahed AS;
    Hepatology; 2007 Jan; 45(1):80-7. PubMed ID: 17187406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial.
    Lok AS; Everhart JE; Chung RT; Padmanabhan L; Greenson JK; Shiffman ML; Everson GT; Lindsay KL; Bonkovsky HL; Di Bisceglie AM; Lee WM; Morgan TR; Ghany MG; Morishima C;
    Clin Gastroenterol Hepatol; 2007 Feb; 5(2):245-54. PubMed ID: 17296533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Insulin resistance in chronic hepatitits C].
    Parise ER; Oliveira AC
    Arq Gastroenterol; 2007; 44(2):178-84. PubMed ID: 17962866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of pegylated interferon α-2b and ribavirin in chronic hepatitis C virus (genotypes 1 and 4) infection.
    Wiśniewska-Ligier M; Pawłowska M; Pilarczyk M; Halota W; Woźniakowska-Gęsicka T
    J Pediatr Gastroenterol Nutr; 2013 Dec; 57(6):694-9. PubMed ID: 23942001
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
    Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
    World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents.
    Al Ali J; Owayed S; Al-Qabandi W; Husain K; Hasan F
    Ann Hepatol; 2010; 9(2):156-60. PubMed ID: 20526008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.